PAMVAC-cVLP is a re-engineered version of the PAMVAC placental malaria (PM) antigen candidate developed by the University of Copenhagen (Denmark). PAMVAC, spanning the CSA-binding ID1-ID2a region of the FCR3-VAR2CSA variant, was previously tested in a combined phase Ia/Ib clinical trial conducted in malaria naïve and exposed nulligravid woman (Mordmüller et al., 2019 - doi: 10.1093/cid/ciy1140). The vaccine was safe, well tolerated and induced good homologous immune responses. In PAMVAC-cVLP the PAMVAC antigen will be coupled to capsid virus-like particles (cVLP), potentially improving immunogenicity, cross-reactivity and longevity of the induced immune response.